All News
Risk of Sepsis or Death Lower with Biologics in Rheumatoid Arthritis
Researchers from Germany have analyzed their large prospective rheumatoid arthritis (RA) registry to address whether being on biologic therapies leads to poorer outcomes - namely sepsis or death, following a serious infection (SIE).
Read Article
ARCTIC Study Shows No Benefit to Ultrasound Remission in RA
The goal in rheumatoid arthritis (RA) treatment is remission. But what level or method of remission is best?
Read Article
Remicade Patent Infringements Denied: Opens Door for New Biosimilars
A U.S. court has affirmed its decision that the patent for Johnson & Johnson's drug Remicade is invalid. This new ruling favors the intent of Celltrion and Pfizer, who are seeking to bring their biosimilar versions of infliximab to market in the near future.
Read Article
Smoking Worsens Rheumatoid Inflammation
Tobacco and chronic smoking is a major risk factor for the onset of rheumatoid arthritis (RA), and chronic smoking has been linked to severity of disease and lower DMARD response rates.
Read Article
Rheumatologists May be Unaware of New Hydroxychloroquine Retinopathy Monitoring Guidelines
Rheumatologists are well-acquainted with the rules for hydroxychloroquine (HCQ) retinopathy screening: A) annual visits to the ophthalmologist and B) maintain HCQ doses at less than 6.5 mg/kg to avoid retinopathy.
Read Article
No Added Lymphoma Risk with TNF Inhibitor Use
Warnings of cancer, especially lymphoma, have accompanied the development and promotion of tumor necrosis factor inhbitors (TNFi) in the treatment of RA and other inflammatory disorders.
Read Article
Cryptochromes Regulate Circadian Inflammation
Circadian rhythms may be disrupted or become exaggerated in a variety of inflammatory conditions. For instance, interleukin-6 (IL-6) and IL-1 have a known circadian cycle to their production, but the same can not be said for TNF.
Read Article
Serious Infections are Not Increased in HIV Patients Treated with TNF Inhibitors
Infections are a concern for many when using tumor necrosis factor-α inhibitor (TNFi) therapy to treat inflammatory disorders. Even moreso in those at higher risk.
Read Article
MRI Findings Match Patients' Experience With RA
Patient-reported outcomes in rheumatoid arthritis (RA) correlate independently with measures of inflammation and structural damage on MRI scans, according to data from a longitudinal study.
Read Article
Nerve Growth Factor Inhibitor Compounds Cartilage Loss in Osteoarthritis
Nerve growth factor (NGF) is a key modulator of pain perception, Inhibitors of NGF are being studied in several chronic pain conditions, including osteoarthritis (OA).
Read Article
Biosimilars are Bioequivalent to Original TNF Inhibitors
Chingcuanco and coinvestigators have reported on their comparative analysis of biosimilars and their originator TNF inhibitors in the current issue of Annals of Internal Medicine. (Citation source: http://buff.ly/2arTd1q)
Read Article
Canakinumab Yields Genetic and Disease Modifying Effects in TRAPS Patients
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autosomal-dominant autoinflammatory disease resulting from mutations of the TNF super family receptor 1A (TNFRSF1A) gene.
RheumNow Week in Review - 29 July 2016
Dr Jack Cush reviews this week's highlights from RheumNow.com.
Read Article
Long-Term Safety of Adalimumab Reviewed
Burmester and colleagues have published their review of the long-term outcomes and safety issues with the TNF inhibitor, adalimumab (ADA). The analysis included 15,132 patients exposed to adalimumab in global RA clinical trials.
Read Article
RheumNow Week in Review – 22 July 2016
From tofacitinib developmental trials in RA and psoriasis and adherence to T2T in early RA to a rheumatology pearl about dapsone and much more, here are the highlights of what you may have missed on RheumNow.com this week.
Read Article
Little Evidence Favoring the Health Benefits of Vitamin D
Vitamin D certainly plays a pivotal role in bone health and immune function.
Read Article
Will Patent Extensions Delay Biosimilar Arrivals?
In the last 6 months, the FDA Arthritis Advisory Committee has recommended three biosimilars (CT-P13, GP-2015, ABP-501) for approval, with one achieving FDA approval Inflectra/CT-P13) and the other two pending a probable approval in the months to come.
Read Article
ORBIT Study Shows Rituximab is Non-Inferior to TNF Inhibitors in Biologic Naive Patients
Porter and colleagues have reported that both rituximab (RTX) and tumour necrosis factor inhibitors (TNFi) are equally and highly effective in early, active, biologic-naive rheumatoid arthritis patients.
Read Article
Increaed GI Perforations with Tocilizumab Seen in German Registry Analysis
The issue of lower intestinal tract perforation (LIP) is no novelty to rheumatologists since the RA treatment paradigm shifted from use of NSAIDs (the most common cause of upper GI tract perforations) to steroids and non-steroidal DMARDs.
Read Article
RheumNow Week in Review – 15 July 2016
Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
Read Article
